Hamburg, Germany, March 23, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced its Seattle-based subsidiary and CDMO, Just – Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimization for a monoclonal antibody cocktail targeting filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV).
The multi-year program award, valued at up to $10 million if all options are activated, will support BARDA’s efforts to strengthen national preparedness by supporting the development of cost‑effective medical countermeasures that can augment the US government’s response capabilities with therapeutics targeting filovirus diseases. The agreement has a base period and two option periods. While two FDA approved therapeutics are currently available for Ebola Virus Disease, no approved treatments exist for infections caused by SUDV.
Linda Zuckerman, EVP Global Head of Biotherapeutics at Just – Evotec Biologics commented, “In outbreak scenarios, speed, scalability and manufacturing robustness are critical. Our technology-driven approach is designed to deliver resilient, industry-leading high-yield production processes that can support rapid deployment in public health emergencies.”
Under the agreement, Just – Evotec Biologics will utilize its validated technology platforms to perform molecular optimization, cell line development, and manufacturing process development for two antibodies. These antibodies, originally identified in survivors of the 2014 Ebola outbreak, represent aspects of an immune response that may have protected infected individuals. Just – Evotec Biologics will apply its platform technologies to convert these discoveries into high-yield, scalable and cost-efficient manufacturing processes capable of supporting future therapeutic development and emergency deployment.
This project has been funded in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority, under OT number #75A50123D00003.
About BARDA
The Biomedical Advanced Research and Development Authority (BARDA) within the US Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR) is responsible for the advanced research, development, and procurement of medical countermeasures, for chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging infectious diseases.
About the Biopharmaceutical Manufacturing Preparedness Consortium
The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) supports BARDA and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of required raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services. The consortium seeks to expand the industrial and manufacturing base for medical countermeasures to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to prepare the United States for future health security threats. Visit biomap-consortium.org to learn more and follow @BioMaP-Consortium on LinkedIn.
